TICKERNERD
Menu
SHCSHCHealthcare · Diagnostics & Research

SHC Stock Forecast: Sotera Health Co. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$19
−1.16% on the day

The 10 Wall Street analysts covering Sotera Health Co. hold a median 12-month price target of $23 — +20.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.3B
Ticker Nerd rank
96 / 100
Median analyst target
$23
Analysts covering
10
Revenue$321.4M+9.2% y/y
Operating income$106.8M
Net income$53.6M
Free cash flow$42.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.0%
1M
+1.2%
YTD
+6.2%
1Y
+17.3%
From 52W high
−4.3%
From 52W low
+42.7%
$13
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sotera Health Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
90
Growth
87
Issuance
84
Revisions
82
Value
81
Momentum
74
Volatility
66
Accruals
54
Size
22

Quality (90): The business earns solid, repeatable profits on what it owns.

Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24$26Oct 25Jan 26Apr 26Jul 26SHCHigh $25Median $23Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $18Median $23High $25

The green dot is the last close — the median target sits +20.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026BarclaysMaintainsOverweight$19 → $22
7 Aug 2026CitigroupMaintainsBuy$23 → $25
7 Aug 2026JP MorganMaintainsNeutral$16 → $18
7 Aug 2026Piper SandlerReiteratesOverweight$22 → $25
24 June 2026BarclaysMaintainsOverweight—
24 June 2026BarclaysMaintainsOverweight$18 → $19
5 June 2026Goldman SachsInitiatesBuy—
6 May 2026Piper SandlerReiteratesOverweight—
14 Apr 2026BarclaysMaintainsOverweight—
24 Feb 2026CitigroupMaintainsBuy—
9 Jan 2026Piper SandlerUpgradeOverweight—
9 Jan 2026RBC CapitalReinstatesOutperform$24
18 Dec 2025William BlairInitiatesOutperform—
13 Nov 2025BMO CapitalInitiatesOutperform—
5 Nov 2025BarclaysMaintainsOverweight—
5 Nov 2025JP MorganMaintainsNeutral—
5 Nov 2025Piper SandlerMaintainsNeutral—
2 Oct 2025BarclaysMaintainsOverweight—
24 June 2025BarclaysMaintainsOverweight—
5 May 2025Goldman SachsUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Sotera Health Co. returned +17.3% against +16.3% for the S&P 500, dividends included.

SHC vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26SHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.2%
Analysts raising
7
Analysts cutting
1
Fundamentals

Sotera Health Co. (SHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.4×

Cheaper than 22% of US stocks

Price / sales
4.4×

Cheaper than 28% of US stocks

Price / book
8.0×

Cheaper than 12% of US stocks

EV / EBITDA
12.6×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
9.2%

Higher than 50% of US stocks

Earnings growth (YoY)
573.7%

Higher than 96% of US stocks

Gross margin
55.4%

Higher than 68% of US stocks

Operating margin
38.0%

Higher than 91% of US stocks

Net margin
13.4%

Higher than 76% of US stocks

Returns & dividend
Return on equity
27.8%

Higher than 87% of US stocks

Return on assets
8.6%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sotera Health Co. (SHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sotera Health Co. has a market value of $5.3B and an enterprise value of $7.3B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 9.2% year on year.

  • Net income over the same four quarters: $163.5M, a 13.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.57.

  • Free cash flow in the twelve months to 30 June 2026: $112.7M.

  • Shares outstanding: 285.4M.

  • Trailing P/E: 33.4×; forward P/E: 17.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sotera Health Co. employs 3,000 people — $405K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

SHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
SHCSotera Health Co.$5.3B
96
BLLNBillionToOne, Inc.$5.0B
15
RDNTRadNet, Inc.$5.9B
36
ADPTAdaptive Biotechnologies Corp.$4.6B
78
GRALGRAIL, Inc.$3.6B
36
VCYTVeracyte, Inc.$3.2B
95
QGENQiagen NV$9.0B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sotera Health Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SHC news & analysis

Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers

Seeking Alpha · 18 Sept 2026positive

A Seeking Alpha article rates Sotera Health as a BUY, citing its vertically integrated model, strong moat in medical equipment sterilization, high customer switching costs, multi-year contracts, and pricing power. It notes Q2 2026 results exceeded expectations and led to raised full-year guidance, with the company trading at a discount to peers despite superior margins.

Why it matters — SHC watchers would care because the article highlights Sotera's durable competitive advantages and pricing power as key growth drivers, supported by a strong quarterly performance that boosted full-year guidance.

Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Sotera Health Company presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the investor conference.

Why it matters — SHC watchers would care because the presentation offers insight into the company's operations and strategy as communicated directly to investors and analysts.

Sotera Health Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Sotera Health reported second-quarter 2026 results featuring 8% constant-currency revenue growth, higher adjusted EBITDA margins, and an upward revision to its full-year revenue and adjusted EBITDA outlook, as detailed in its Q2 earnings call.

Why it matters — Sotera Health watchers would note that the company raised its full-year revenue and adjusted EBITDA guidance while reporting improved margins and revenue growth.

Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Sotera Health Company's Q2 2026 earnings call, which covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — A SHC watcher would care because the transcript offers direct insight into how management discussed the company's quarterly performance and its forward-looking outlook.

Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 6 Aug 2026neutral

Zacks reports on Sotera Health's (SHC) Q2 earnings for the quarter ended June 2026, examining how its revenue and EPS compare with Wall Street estimates and year-ago figures. The piece focuses on key metrics versus analyst expectations rather than detailing actual numerical results.

Why it matters — SHC watchers would care because the comparison of Q2 metrics against Wall Street estimates indicates whether the company met analyst expectations for the quarter.

FAQ

Frequently asked questions about SHC stock

What is the SHC stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Sotera Health Co. have a median 12-month price target of $23, with estimates ranging from $18 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SHC stock a buy right now?

Of the 10 analysts covering Sotera Health Co., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sotera Health Co. 96 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SHC?

As at 19 Sept 2026, Sotera Health Co. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).

Will SHC stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +20.1% from the last close, and Ticker Nerd's factor model ranks Sotera Health Co. 96 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SHC stock forecast for 2030?

No analyst covering Sotera Health Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $25 over the next 12 months.

How has SHC stock performed over the past year?

Sotera Health Co. returned +17.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sotera Health Co. do?

Sotera Health Company is a healthcare services company that provides sterilization solutions, laboratory testing, and advisory services for medical device, pharmaceutical, life sciences, and food-related products. Through its Sterigenics, Nordion, and Nelson Labs businesses, the company supports product safety, contamination control, and regulatory compliance across critical stages of development and manufacturing.

What is the latest news on SHC?

The most recent item we track (Seeking Alpha, 18 Sept 2026): "Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers". A Seeking Alpha article rates Sotera Health as a BUY, citing its vertically integrated model, strong moat in medical equipment sterilization, high customer switching costs, multi-year contracts, and pricing power. It notes Q2 2026 results exceeded expectations and led to raised full-year guidance, with the company trading at a discount to peers despite superior margins.

Company

About Sotera Health Co.

Sotera Health Company is a healthcare services company that provides sterilization solutions, laboratory testing, and advisory services for medical device, pharmaceutical, life sciences, and food-related products. Through its Sterigenics, Nordion, and Nelson Labs businesses, the company supports product safety, contamination control, and regulatory compliance across critical stages of development and manufacturing. Sterigenics offers outsourced terminal sterilization and irradiation services, Nordion supplies cobalt-60 and gamma irradiation technologies, and Nelson Labs delivers microbiological and analytical chemistry testing. Sotera Health serves customers in North America, Europe, and other international markets, making it an important provider of mission-critical services that help protect patients, consumers, and healthcare professionals.

CEO Mr. Alton E. Shader · 3,000 employees · United States · https://soterahealth.com